Zobrazeno 1 - 10
of 17
pro vyhledávání: '"K R, Wilske"'
Publikováno v:
Clinical and Experimental Immunology. 112:516-527
SUMMARYThe human antibody repertoire has been demonstrated to have a marked V-gene-dependent bias that is conserved between individuals. In RA patients, certain heavy chain V genes (VH) have been found to be preferentially used for encoding autoantib
Autor:
G R, Burmester, K R, Wilske
Publikováno v:
Rheumatology (Oxford, England). 38
Publikováno v:
The Journal of rheumatology. 23(9)
Publikováno v:
The Journal of rheumatology. 21(2)
The relationship between rheumatoid factor positive (RF+) and rheumatoid factor negative (RF-) rheumatoid arthritis (RA) is controversial. We sought to determine whether the HLA genes conferring susceptibility for erosive RF+RA are also prevalent in
Autor:
K R, Wilske
Publikováno v:
British journal of rheumatology. 32
In evaluating current therapy of RA, it is becoming recognized that sequential single drug treatment, as exemplified by the traditional therapeutic pyramid, is often too little and too late in patients with aggressive 'at risk' synovitis. Evidence ex
Autor:
K R, Wilske, L A, Healey
Publikováno v:
Rheumatic diseases clinics of North America. 19(1)
We are on the threshold of a new era in the treatment of RA if we learn from the experience of the past and utilize new techniques and therapeutic modalities that the future will bring. New strategies and treatment of RA in the future will need to in
Autor:
L A, Healey, K R, Wilske
Publikováno v:
The Journal of rheumatology. 18(5)
Autor:
K R, Wilske, L A, Healey
Publikováno v:
The Journal of rheumatology. Supplement. 25
Traditional therapy of rheumatoid arthritis (RA) has been dominated by the therapeutic pyramid. This approach is not working. The designation of drugs as either antiinflammatory or disease modifying is not borne out by experience. We possess a number
Autor:
K R, Wilske, P M, Campbell
Publikováno v:
Bulletin on the rheumatic diseases. 37(2)
Publikováno v:
The New England journal of medicine. 295(16)